Treatment of @entity628 with pulse steroids and oral XXXX .

@entity1 @entity1667 @entity2313 @entity644 @entity101 @entity628 @entity786 @entity177 @entity134 @entity619 @entity281 @entity1011 @entity1985 @entity617 @entity288
@entity1 with @entity134 -resistant @entity1985 often have an unsatisfactory long-term outcome and are at risk of developing @entity177 . We prospectively treated 65 @entity1 with idiopathic @entity134 -resistant @entity1985 and @entity628 ( @entity628 ) with intravenous pulses of @entity288 and oral @entity786 . @entity619 (5 mg/kg) or @entity1667 (30 mg/kg) was administered intravenously, initially 6 pulses on alternate days, followed by 4 fortnightly and 8 monthly pulses. Oral @entity786 therapy was given for 12 weeks and tapering doses of @entity617 were administered for 52 weeks. The mean age at treatment was 85.7+/- 44.9 months. Five @entity1 developed serious @entity281 during administration of initial alternate-day pulses and were excluded. Of 59 @entity1 who completed initial alternate-day therapy, 17 had complete and 8 partial remission; 34 (57.6%) @entity1 did not respond to treatment. The median urine protein to @entity1011 ratio decreased from 10.0 to 0.75 (P<0.005) and serum @entity2313 increased from 1.9 g/dl to 2.4 g/dl (P<0.01). The median duration of follow-up after stopping pulse therapy was 25.6 months. Thirty-four @entity1 were followed for more than 3 years (median 4.5 years). Of these, 22 (64.7%) @entity1 had a favorable outcome; persistent complete remission was seen in 15 @entity1 and @entity134 -responsive relapses in 7. Seven @entity1 had non- @entity1985 -range @entity644 , 2 had @entity1985 -range @entity644 , and 3 (8.8%) were in @entity177 . There was no significant difference in the short- and long-term outcome of @entity1 with initial (n=28) and late resistance (n=31). The outcome in @entity1 receiving intravenous @entity619 (n=48) or @entity1667 (n=11) was also similar. The chief side effects included worsening of height standard deviation score (47.4%), transient @entity101 (42.5%), and serious @entity281 (18.5%). We conclude that prolonged treatment with intravenous @entity288 and oral @entity786 is beneficial in @entity1 with @entity134 -resistant @entity628 . Expensive protocols can be successfully modified and used, depending upon the availability of health resources.
